Related Experiment Video

Updated: Mar 11, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.0K

Potential Psychiatric Uses for MDMA

B B Yazar-Klosinski1, M C Mithoefer1

  • 1Multidisciplinary Association for Psychedelic Studies, Santa Cruz, California, USA.

Clinical Pharmacology and Therapeutics
|November 19, 2016
PubMed

Insights

Phase II trials show 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy is safe and effective for posttraumatic stress disorder (PTSD). This approach may also help depression and anxiety, potentially using expedited FDA review.

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience

Background:

  • Posttraumatic stress disorder (PTSD) is a debilitating condition with limited treatment options.
  • Current treatments for PTSD, depression, and anxiety disorders often have suboptimal efficacy and side effect profiles.

Purpose of the Study:

  • To evaluate the safety and efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for PTSD.
  • To explore the potential of MDMA-assisted psychotherapy for treating depression and anxiety disorders.
  • To assess the suitability of this therapeutic model for accelerated regulatory review.

Main Methods:

  • Phase II clinical trials involving the administration of single doses of MDMA within a structured psychotherapy framework.
  • Comparison of MDMA-assisted psychotherapy with traditional daily drug administration models.

Main Results:

  • Demonstrated initial safety and efficacy of MDMA-assisted psychotherapy in Phase II trials for PTSD.
  • Identified potential for expansion of this therapeutic model to depression and anxiety disorders.

Conclusions:

  • MDMA-assisted psychotherapy represents a promising novel approach for PTSD treatment.
  • The unique model of single-dose administration within psychotherapy may facilitate expedited regulatory pathways, such as FDA Breakthrough Therapy Designation.

More Related Videos

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.3K
Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones06:06

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

27.0K

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
933
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
860
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
755
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.0K
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
1.5K